Drug Profile
Research programme: cancer therapeutics - Heidelberg Pharma Research
Alternative Names: HDP 15.0001; HDP 150001Latest Information Update: 13 Oct 2017
Price :
$50
*
At a glance
- Originator Heidelberg Pharma
- Class Purine nucleosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
- 16 May 2005 Preclinical trials in Non-Hodgkin's lymphoma in Germany (unspecified route)
- 16 May 2005 Preclinical trials in Solid tumours in Germany (unspecified route)